Aspire Biopharma Details Highly Dilutive Series A Convertible Preferred Stock Terms

summarizeSummary

Aspire Biopharma Holdings, Inc. filed a Certificate of Designation for Series A Convertible Preferred Stock, revealing highly dilutive terms including a floating conversion price, price protection, and liquidation preferences, which are significantly unfavorable to common shareholders.

check_boxKey Events

• Designation of Series A Preferred Stock

  The company designated 25,000 shares as Series A Convertible Preferred Stock, finalizing the terms of the capital raise initiated on January 30, 2026.

• Highly Dilutive Conversion Terms

  Shares are convertible at 80% of the lowest closing price over five days, with a floor price, and subject to a 19.99% conversion cap without shareholder approval.

• Price Protection Clause

  The conversion price will be reduced if the company issues future securities at a lower effective price, a feature highly detrimental to common shareholders.

• Liquidation Preference

  Series A holders have a liquidation preference of $1,000 per share plus accrued dividends, or the common stock equivalent, whichever is greater.

auto_awesomeAnalysis

This 8-K filing provides critical details regarding the Series A Convertible Preferred Stock, which finalizes the terms of the $2 million capital raise announced on January 30, 2026. The terms of this preferred stock are exceptionally dilutive and unfavorable for existing common shareholders. Key features include a floating conversion price (80% of the lowest closing price over five days), a "price protection" (ratchet) clause that automatically lowers the conversion price if the company issues future securities at a lower effective price, and a liquidation preference. These provisions are characteristic of "toxic" financing, often employed by companies in severe financial distress, and will likely exert significant downward pressure on the common stock as the preferred shares convert. The extensive list of "Triggering Events" further exposes the company to forced conversions at discounted prices. This financing, while potentially providing short-term capital, comes at a very high cost to equity holders.